Wide Ranks

HROW

Harrow, Inc.

42.47

Top Statistics
Market Cap 1 B Forward PE 54.45 Revenue Growth 43.80 %
Current Ratio 1.55 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -19.75 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 586.92 Enterprise / Revenue 9.50 Price To Sales Trailing12 Months 8.94
Profitability
Profit Margins -19.75 % Operating Margins 2.68 %
Balance Sheet
Total Cash 72 M Total Cash Per Share 2.06 Total Debt 186 M
Total Debt To Equity 322.90 Current Ratio 1.55 Book Value Per Share 1.64
All Measures
Short Ratio 376.00 % Message Board Id finmb_21993612 Shares Short Prior Month 3 M
Return On Equity -0.5023 City Nashville Uuid 2d3d154a-7423-3544-9b38-aa85176d4703
Previous Close 42.24 First Trade Date Epoch Utc 1 B Book Value 1.64
Total Debt 186 M Volume 323453 Price To Book 25.91
Last Split Date 1 B Fifty Two Week Low 8.86 Total Cash Per Share 2.06
Total Revenue 169 M Shares Short Previous Month Date 1 B Target Median Price 60.00
Max Age 86400 Recommendation Mean 1.00 Sand P52 Week Change 0.3133
Operating Margins 2.68 % Target Mean Price 60.85 Net Income To Common -33406000
Short Percent Of Float 0.0996 Implied Shares Outstanding 35 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 792610 Average Volume10days 792610
Total Cash 72 M Next Fiscal Year End 1 B Revenue Per Share 4.76
Held Percent Insiders 0.1411 Ebitda Margins 1.62 % Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 42.24
Target Low Price 50.40 Gmt Off Set Milliseconds -18000000 Fifty Day Average 47.76
Open 42.47 Free Cashflow -100520000 State TN
Dividend Yield 0.00 % Return On Assets -0.0168 Time Zone Short Name EST
Trailing Eps -0.9500 Day Low 41.79 Address1 102 Woodmont Boulevard
Shares Outstanding 35 M Price Hint 2 Target High Price 73.00
Website https://www.harrow.com 52 Week Change 3.60 Average Volume 535723
Forward Eps 1.03 Recommendation Key strong_buy Compensation As Of Epoch Date 1 B
Quick Ratio 76.40 % Last Split Factor 1:5 Regular Market Day High 43.68
Is_sp_500 False Profit Margins -19.75 % Debt To Equity 322.90
Fifty Two Week High 59.23 Day High 43.68 Shares Short 2 M
Regular Market Open 42.47 Industry Key drug-manufacturers-specialty-generic Earnings Growth 0.00 %
Enterprise To Revenue 9.50 Revenue Growth 43.80 % Shares Percent Shares Out 0.0704
Operating Cashflow 4 M Currency USD Time Zone Full Name America/New_York
Market Cap 1 B Is_nasdaq_100 False Zip 37205
Quote Type EQUITY Industry Drug Manufacturers - Specialty & Generic Long Name Harrow, Inc.
Regular Market Day Low 41.79 Held Percent Institutions 0.5916 Current Price 42.47
Address2 Suite 610 Enterprise To Ebitda 586.92 Financial Currency USD
Current Ratio 1.55 Gross Margins 72.56 % Industry Disp Drug Manufacturers - Specialty & Generic
Number Of Analyst Opinions 4 Country United States Float Shares 26 M
Two Hundred Day Average 27.40 Enterprise Value 1 B Price To Sales Trailing12 Months 8.94
Forward PE 54.45 Regular Market Volume 323453 Ebitda 2 M
Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products.

The company offers ImprimisRx, an ophthalmology-focused compounded medications.

It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis.

In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop.

Further, the company has collaboration with Asembia to enhance provider and patient experience through nationwide digital services and hub support for harrow's branded eyecare products.

The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023.

Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.